These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21248619)

  • 21. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
    Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
    Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied D; Bode C
    Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
    Leonardi S; Tricoci P; Becker RC
    Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
    Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
    N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
    Gryka RJ; Buckley LF; Anderson SM
    Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
    Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAR-1 antagonists: current state of evidence.
    Chatterjee S; Sharma A; Mukherjee D
    J Thromb Thrombolysis; 2013 Jan; 35(1):1-9. PubMed ID: 22644721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorapaxar.
    Am J Cardiovasc Drugs; 2010; 10(6):413-8. PubMed ID: 21090833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
    Leonardi S; Tricoci P; Becker RC
    Drugs; 2010 Oct; 70(14):1771-83. PubMed ID: 20836572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
    Chackalamannil S; Wang Y; Greenlee WJ; Hu Z; Xia Y; Ahn HS; Boykow G; Hsieh Y; Palamanda J; Agans-Fantuzzi J; Kurowski S; Graziano M; Chintala M
    J Med Chem; 2008 Jun; 51(11):3061-4. PubMed ID: 18447380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of emerging novel platelet inhibitors.
    Angiolillo DJ; Capranzano P
    Am Heart J; 2008 Aug; 156(2 Suppl):S10-5. PubMed ID: 18657681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
    Leonardi S; Becker RC
    Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges and promises of developing thrombin receptor antagonists.
    Yang J; Xu K; Seiffert D
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.